Compare · LBRX vs NVO
LBRX vs NVO
Side-by-side comparison of LB Pharmaceuticals Inc (LBRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 247.4x LBRX ($900.7M).
- NVO has been more active in the news (5 items in the past 4 weeks vs 4 for LBRX).
- NVO has more recent analyst coverage (25 ratings vs 7 for LBRX).
- Company
- LB Pharmaceuticals Inc
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $900.7M
- $222.81B
- 1M return
- -
- +15.47%
- 1Y return
- -
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 5
- Recent ratings
- 7
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LBRX
- SEC Form SCHEDULE 13G filed by LB Pharmaceuticals Inc
- LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- Wolfe Research initiated coverage on LB Pharmaceuticals with a new price target
- LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
- SEC Form 8-K filed by LB Pharmaceuticals Inc
- SEC Form 144 filed by LB Pharmaceuticals Inc
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
- SEC Form 8-K filed by LB Pharmaceuticals Inc
- SEC Form 4 filed by Director Ruffolo Robert R
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S